Department of Biotechnology, Yonsei University, Seoul, 03722, Republic of Korea.
Cellartgen, Seoul, 03722, Republic of Korea.
Nat Commun. 2024 Mar 22;15(1):2564. doi: 10.1038/s41467-024-46928-y.
Engineered human cardiac tissues have been utilized for various biomedical applications, including drug testing, disease modeling, and regenerative medicine. However, the applications of cardiac tissues derived from human pluripotent stem cells are often limited due to their immaturity and lack of functionality. Therefore, in this study, we establish a perfusable culture system based on in vivo-like heart microenvironments to improve human cardiac tissue fabrication. The integrated culture platform of a microfluidic chip and a three-dimensional heart extracellular matrix enhances human cardiac tissue development and their structural and functional maturation. These tissues are comprised of cardiovascular lineage cells, including cardiomyocytes and cardiac fibroblasts derived from human induced pluripotent stem cells, as well as vascular endothelial cells. The resultant macroscale human cardiac tissues exhibit improved efficacy in drug testing (small molecules with various levels of arrhythmia risk), disease modeling (Long QT Syndrome and cardiac fibrosis), and regenerative therapy (myocardial infarction treatment). Therefore, our culture system can serve as a highly effective tissue-engineering platform to provide human cardiac tissues for versatile biomedical applications.
已将工程化的人类心脏组织用于各种生物医学应用,包括药物测试、疾病建模和再生医学。然而,由于其不成熟和功能缺乏,源自人类多能干细胞的心脏组织的应用往往受到限制。因此,在这项研究中,我们建立了基于类似体内心脏微环境的可灌注培养系统,以改善人类心脏组织的制造。微流控芯片和三维心脏细胞外基质的集成培养平台增强了人类心脏组织的发育及其结构和功能的成熟。这些组织由心血管谱系细胞组成,包括源自人诱导多能干细胞的心肌细胞和心脏成纤维细胞,以及血管内皮细胞。所得的大规模人类心脏组织在药物测试(具有不同程度心律失常风险的小分子)、疾病建模(长 QT 综合征和心脏纤维化)和再生治疗(心肌梗死治疗)方面显示出更好的效果。因此,我们的培养系统可以作为一个高效的组织工程平台,为各种生物医学应用提供人类心脏组织。